QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=7B1F6693B270947344DE4E5335DCA1D3;jsessionid=377AA20F3F2C7040DFFDB9EF090E8E80;jsessionid=5DEF7EFA4D41072573B10DCEBD2987D4;jsessionid=EFA1E7181EBE5963C1CD1302AC981F02;jsessionid=BFD9BE0915696EDC387485B570267695;jsessionid=24F7B41FDCF59C26A26C553FA0B0658D (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=7B1F6693B270947344DE4E5335DCA1D3;jsessionid=377AA20F3F2C7040DFFDB9EF090E8E80;jsessionid=5DEF7EFA4D41072573B10DCEBD2987D4;jsessionid=EFA1E7181EBE5963C1CD1302AC981F02;jsessionid=BFD9BE0915696EDC387485B570267695;jsessionid=24F7B41FDCF59C26A26C553FA0B0658D